

## Subject Index

### A

- Aclacinomycin**, and 7-con-*O*-methylnogarol (7-OMEN), failure to decrease cardiac guanylate cyclase activity, 1127
- ACNU (3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea)**, distribution, excretion, and metabolism of, in rats and mice after iv administration, 575
- 4'-(9-Aridinylamino)methanesulfon-m-aniside** *see* AMSA
- Actinomycin D**, combined with vincristine and cyclophosphamide followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689
- Adenocarcinoma** *see* Cancer, adenocarcinoma
- Adenosine**, selective protection of cells from 6-thioguanine and 6-mercaptopurine by: biochemical approaches to the enhancement of antitumor drug selectivity, 1347
- Adrenal cortical cancer** *see* Cancer, adrenal cortical
- Adriamycin (doxorubicin)**  
and CCNU, compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of small cell bronchogenic cancer, 997  
and *cis*-diamminedichloroplatinum(II), sequential combination chemotherapy with vinblastine and bleomycin in disseminated nonseminomatous testicular cancer, 599  
combined with bleomycin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717  
combined with *cis*-diamminedichloroplatinum(II) and *Corynebacterium parvum* in the treatment of non-small cell lung cancer, 1367  
combined with cyclophosphamide and bleomycin, in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001  
combined with cyclophosphamide and *cis*-diamminedichloroplatinum(II) (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655  
combined with cyclophosphamide and *cis*-diamminedichloroplatinum(II), lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311  
combined with cyclophosphamide and 5-FU in the treatment of carcinoma of the cervix or vagina, 549  
combined with cyclophosphamide and high-dose methotrexate with leucovorin rescue in the treatment of measurable primary or metastatic osteosarcoma, 11  
combined with cyclophosphamide in the treatment of advanced recurrent squamous cell carcinoma, 1363  
combined with cyclophosphamide, vincristine, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 93  
combined with cyclophosphamide, vincristine, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649  
combined with 5-FU, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157  
combined with 5-FU, phase II study of, in the treatment of transitional cell carcinoma of the urinary tract, 161  
combined with ifosfamide in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study, 869  
combined with melphalan and vincristine in the treatment of advanced breast cancer, 1015  
combined with ricin in the treatment of L1210 mouse leukemia, 1375  
combined with triazinate, cyclophosphamide, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925  
combined with vincristine and cyclophosphamide and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65  
combined with vincristine, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371  
combined with VM-26, bleomycin, and prednisone as a secondary treatment of malignant lymphoma, 335  
combined with VP-16-213, cyclophosphamide, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135  
distribution of, in mice under conditions of local hyperthermia which improve systemic drug therapy, 203  
early phase pharmacokinetics of, in plasma of cancer patients during single- or multiple-drug therapy, 845  
effect of, on the cell kinetics of 13762 rat mammary tumors and implications for therapy, 293  
evaluation of vitamin E and selenium protection against chronic doxorubicin toxicity in rabbits, 315  
given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity, 47  
intra-arterial infusion of, review of responses, 31  
and methotrexate, given after combination of vincris-

- tine, actinomycin D, and cyclophosphamide in the treatment of advanced sarcoma, 689
- neurotoxicity of, in rats: a low-dose effect, 257
- randomized comparison of two combination chemotherapy regimens containing, in patients with metastatic breast cancer: a Western Cancer Study Group trial, 981
- studies on the comparative distribution and biliary excretion of, with 4'-epi-doxorubicin, in mice and rats, 897
- AMSA**
- acute ventricular fibrillation and death during infusion of, 356
  - multiple ventricular extrasystoles following administration of, 358
  - phase I evaluation of, by a weekly iv dose schedule, 53
  - phase II evaluation of, in the treatment of advanced colorectal carcinoma, 1149
  - phase II evaluation of, in the treatment of metastatic lung cancer, 1388
  - phase II evaluation of, in the treatment of non-small cell lung cancer, 345
  - phase II study of, in the treatment of advanced sarcoma, 1129
  - phase II trial of, in the treatment of advanced non-Hodgkin's lymphoma, 1157
  - phase II trial of, in the treatment of metastatic hypernephroma, 183
  - phase II trial of, in the treatment of metastatic renal cell carcinoma, 1009
  - preclinical toxicologic evaluation of, in mice, dogs, and monkeys, 855
- AD 32 (*N*-trifluoroacetyladriamycin-14-valerate)**, possible relevance of AD 41 in the antitumoral activity of, in tumor-bearing mice: pharmacokinetic evidence, 873
- AD 41 (*N*-trifluoroacetyladriamycin)**, possible relevance of, in the antitumoral activity of AD 32 in tumor-bearing mice: pharmacokinetic evidence, 873
- Adenosine deaminase**, distribution and inhibition of, in tissues of man, rat, and mouse, 629
- Adverse effects, animals**
- effect of gentamicin and irradiation on the toxicity of high-dose methotrexate in rats, 989
  - evaluation of vitamin E and selenium protection against chronic doxorubicin toxicity in rabbits, 315
  - neurotoxicity of doxorubicin in rats: a low-dose effect, 257
  - selective inhibition of the nephrotoxicity of *cis*-diamminedichloroplatinum(II) by WR-2721 without altering its antitumor properties, 57
  - toxicity of spirogermanium in mice and dogs after iv or im administration, 1207
- Adverse effects, man**
- acute ventricular fibrillation and death during infusion of AMSA, 356
  - doxorubicin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity, 47
  - anaphylaxis due to oral melphalan, 731
  - augmentation of vincristine neurotoxicity by irradiation of peripheral nerves, 963
  - avascular necrosis of the femoral head: association with adjuvant chemotherapy for breast carcinoma, 361
  - cardiomyopathy in adults after combination doxorubicin and DTIC, 353
  - cellulitis and fibrosis due to *cis*-diamminedichloroplatinum(II) infiltration, 1162
  - changes in hair pigmentation associated with cancer chemotherapy, 193
  - chemotherapy-induced emesis, double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on, 219
  - cholestatic jaundice associated with chlorozotocin, 1235
  - clinical pharmacologic effects of thymidine plus 5-FU, 1169
  - coronary artery disease after treatment with bleomycin and vinblastine, 1159
  - early detection of lung toxicity after bleomycin therapy, 732
  - failure of aclacinomycin and 7-con-*O*-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity, 1127
  - fatal hepatic necrosis after high-dose chemotherapy following haloalkane anesthesia, 1023
  - fatal pulmonary bleomycin toxicity in *cis*-diamminedichloroplatinum(II)-induced acute renal failure, 921
  - hepatotoxicity of hycanthone in patients with metastatic breast cancer, 929
  - lactic acidosis associated with metastatic breast carcinoma, 1283
  - leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue, 1261
  - multiple ventricular extrasystoles following administration of AMSA, 358
  - photosensitivity reaction following DTIC administration: report of two cases, 725
  - respiratory dyskinesia associated with hexamethylmelamine, 355
  - severe skin necrosis produced by piperazinedione extravasation, 1392
  - skin rashes associated with the administration of the 2-nitroimidazole, misonidazole, 263
  - vincristine-induced orthostatic hypotension: a prospective clinical study, 359
- 3-[*(4*-Amino-2-methyl-5-pyrimidinyl)-methyl]-1-(2-chloroethyl)-1-nitrosourea** see ACNU
- Amygdalin** see Laetrile
- Anaphylaxis** see Adverse effects, man
- L-Asparaginase**
- combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
  - and methotrexate, sequential combination of, in the treatment of refractory acute leukemia, 939
  - phase II study of, in the treatment of pancreatic carcinoma, 1359

## B

**Baker's antifol** see also Triazinate

- combined with 5-FU and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247
- phase II trial of, in the treatment of metastatic renal cell carcinoma: a Southwest Oncology Group study, 1387
- BAMP (bleomycin, doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum[II]),** in the treatment of non-small cell bronchogenic carcinoma, 717
- Benzaldehyde,** antitumor activity of, 21
- Bladder cancer** *see* Cancer, bladder
- Bleomycin**
- alone or combined with mitomycin C in the treatment of advanced or recurrent squamous cell carcinoma of the vulva, 689
  - combined with *cis*-diamminedichloroplatinum(II) and vinblastine in the treatment of mediastinal germ-cell tumors: complete remission of, 319
  - combined with cyclophosphamide and doxorubicin, in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001
  - combined with doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717
  - combined with mitomycin C in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study, 1139
  - combined with vinblastine and followed sequentially by *cis*-diamminedichloroplatinum(II), actinomycin D, and vincristine in the treatment of metastatic testicular cancer, 553
  - combined with vinblastine, coronary artery disease after treatment with, 1159
  - combined with vinblastine in the treatment of metastatic melanoma, 138
  - combined with vincristine and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma, 943
  - combined with vincristine, doxorubicin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371
  - combined with vincristine, mitomycin C, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005
  - combined with VM-26, doxorubicin, and prednisone as a secondary treatment of malignant lymphoma, 335
  - early detection of lung toxicity after therapy with, 732
  - epidermal cell kinetics in hairless mice after: perturbations after multiple doses, 1039
  - intermittent, combined with vinblastine and single-dose *cis*-diamminedichloroplatinum(II) in the management of stage III testicular cancer, 331
  - intra-arterial infusion of, review of responses, 31
  - relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A, 659
  - and vinblastine, sequential combination chemotherapy with doxorubicin and *cis*-diamminedichloroplatinum(II) in disseminated nonseminomatous testicular cancer, 599

- B16 melanoma** *see* Tumor systems, animals
- BOMP (bleomycin, vincristine, mitomycin C, and *cis*-diamminedichloroplatinum[II]),** in the treatment of advanced cervical cancer, 1005
- Brain cancer** *see* Cancer, brain
- Breast cancer** *see* Cancer, breast
- Bronchogenic carcinoma** *see* Cancer, lung

## C

- Caffeine,** combined with chlorpromazine and methyl-CCNU in the treatment of disseminated melanoma, 151
- CAMP (CCNU, melphalan, methotrexate, and prednisone),** versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635
- Cancer** *see also* Leukemia
- adenocarcinoma, advanced endometrial, tamoxifen in the treatment of, 805
  - adrenal cortical, cytotoxic chemotherapy in the treatment of, 909
  - bladder, low-grade, low-stage transitional cell, phase I-II study of mitomycin C topical therapy in the treatment of: an interim report, 225
  - brain
    - evaluation of agents (doxorubicin, bleomycin, dianhydrogalactitol, VM-26, epodol, 5-FU, DTIC, BIC, methotrexate, mithramycin, mechlorethamine, BCNU, CCNU, methyl-CCNU, procarbazine, thioTEPA, vincristine, bromouridine, hydroxyurea, metronidazole, and misonidazole) in current use for phase II and III trials, 1179
    - malignant tumor, modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of, 237
  - breast
    - advanced, CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of, in postmenopausal women, 635
    - advanced, combination of levamisole immunotherapy and polychemotherapy in the treatment of, 65
    - advanced, danazol in the treatment of, 1073
    - advanced, male, use of tamoxifen in, 801
    - advanced, melphalan, doxorubicin, and vincristine in the treatment of, 1015
    - advanced, phase II evaluation of vindesine in the treatment of, 693
    - advanced, tamoxifen or fluoxymesterone in the treatment of: a controlled clinical trial, 117
  - avascular necrosis of the femoral head: association with adjuvant chemotherapy for, 361
  - clinical pharmacology of tamoxifen in patients with: comparison of traditional and loading-dose schedules, 765
  - comparisons of cooperative group evaluation criteria for multiple-drug therapy for, 507
  - initial clinical study with PALA in the treatment of, 617

- metastatic, chemoimmunotherapy for, with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine, 157  
 metastatic, hepatotoxicity of hycanthone in patients with, 929  
 metastatic, lactic acidosis associated with, 1283  
 metastatic, phase II trial of 6-thioguanine in the treatment of, 191  
 metastatic, randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with: a Western Cancer Study Group trial, 981  
 metastatic, sequential use of endocrine therapy and chemotherapy in the treatment of: effects on survival, 111  
 metastatic, tamoxifen therapy in premenopausal patients with, 787  
 phase II trial of vindesine in the treatment of, 1001  
 refractory advanced, vinblastine given as a continuous 5-day infusion in the treatment of, 279  
 refractory, effectiveness of intermediate-dose methotrexate and high-dose 5-FU as sequential combination chemotherapy in the treatment of, 829  
 refractory, minimal single-agent activity of maytansine in: a Southwest Oncology Group study, 675  
 salvage treatment of patients relapsing after adjuvant chemotherapy for, 269  
 stage IV, antiestrogen-induced remissions in premenopausal women with: effects on ovarian function, 779  
**cervical**  
 advanced, BOMP (bleomycin, vincristine, mitomycin C, and *cis*-diamminedichloroplatinum(II)) in the treatment of, 1005  
 doxorubicin, cyclophosphamide, and 5-FU in the treatment of, 549  
 far-advanced, mitomycin C and bleomycin in the treatment of: a Southwest Oncology Group pilot study, 1139  
**colon**  
 metastatic adenocarcinoma, phase II evaluation of PALA in the treatment of, 339  
 metastatic, effectiveness of intermediate-dose methotrexate and high-dose 5-FU as primary therapy in the treatment of, 829  
**colorectal**  
 advanced metastatic, phase III study of ICRF-159 versus 5-FU in the treatment of, 1047  
 advanced, phase II evaluation of AMSA in the treatment of, 1149  
 advanced, phase II evaluation of PALA in the treatment of, 349  
 advanced, phase II study of fluorodopan in the treatment of, 697  
 advanced, triazinate, ICRF-159, 5-FU, and methyl-CCNU in the treatment of, 1143  
 metastatic, Baker's antifol combined with 5-FU and methyl-CCNU in the treatment of: a Southwest Oncology Group study (protocol 7764), 247  
 metastatic human, lack of clinical therapeutic syn-
- ergism between cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in, 311  
 esophageal, *cis*-diamminedichloroplatinum(II) in the treatment of, 709  
 gastric, effects of chemotherapy with mitomycin C and 5-FU on pancreatic functions in patients with, 1151  
 germ-cell, mediastinal, complete remission of, with the combination of *cis*-diamminedichloroplatinum(II), bleomycin, and vinblastine, 319  
**head and neck**  
 advanced, phase II trial of vindesine in the treatment of, 1141  
 advanced squamous cell, combination chemotherapy in the treatment of, 187  
 previously treated squamous cell, phase II study of flurafur in the treatment of, 713  
**lung**  
 advanced adenocarcinoma, phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in the treatment of, 925  
 advanced, phase II clinical trial of high-dose *cis*-diamminedichloroplatinum(II) with fluid- and mannitol-induced diuresis in the treatment of, 1241  
 extensive adenocarcinoma and large cell undifferentiated, combination chemotherapy with 5-FU, vincristine, and mitomycin C in the treatment of, 1241  
 extensive non-small cell, single-agent and combination chemotherapy for, 685  
 metastatic, phase II evaluation of triazinate in the treatment of, 1057  
 non-small cell, combination chemotherapy with bleomycin, doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of, 717  
 non-small cell, doxorubicin, *cis*-diamminedichloroplatinum(II), and *Corynebacterium parvum* in the treatment of, 1367  
 non-small cell, high-dose methotrexate in the treatment of: an Eastern Cooperative Oncology Group study, 1017  
 non-small cell, phase II evaluation of AMSA in the treatment of, 345  
 non-small cell, phase II evaluation of PALA in the treatment of, 705  
 phase II evaluation of AMSA in the treatment of, 1383  
 small cell, CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of, 997  
 small cell, results of whole-brain irradiation for metastases from, 957  
 small cell undifferentiated, update of recent results, 539  
 squamous cell, a role of *cis*-diamminedichloroplatinum(II) in the treatment of, 87  
 stage III non-small cell, high-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of: a randomized trial, 1131

- lymphoma**
- advanced cutaneous T-cell, combination chemotherapy (vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone) in the treatment of, 1371
  - advanced diffuse histiocytic, treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy, 649
  - advanced non-Hodgkin's, phase II trial of AMSA in the treatment of, 1157
  - advanced, phase II study of maytansine in the treatment of: an Eastern Cooperative Oncology Group pilot study, 1115
  - Burkitt's, tumor lysis following malignant hyperthermia, 327
  - localized diffuse histiocytic, curative radiotherapy for, 175
  - malignant, ifosfamide, methotrexate, and vincristine combined as secondary treatment for patients with, 933
  - malignant, VM-26 combined with doxorubicin, bleomycin, and prednisone as a secondary treatment of, 335
  - non-Hodgkin's, *cis*-diamminedichloroplatinum(II) with and without ICRF-159 in the treatment of, 301
  - non-Hodgkin's, VP-16-213 combined with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of, 1135
  - phase II trial of vindesine in the treatment of, 1001
  - refractory malignant, randomized clinical trial comparing two dose regimens of ICRF-159 in the treatment of, 1355
- melanoma**
- disseminated cutaneous malignant, combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine: 3 years' followup, 143
  - disseminated malignant, phase II study of maytansine and chlorozotocin in the treatment of, 721
  - disseminated malignant, phase II study of tamoxifen in the treatment of, 199
  - disseminated, randomized trial of chlorpromazine, caffeine, and methyl-CCNU in the treatment of, 151
  - malignant, estrogen and progesterone receptors and tamoxifen in, 819
  - malignant, phase II trial of vindesine in the treatment of, 179
  - metastatic malignant, DTIC in the treatment of: a simplified dose schedule, 1123
  - metastatic malignant, procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of, 139
  - metastatic malignant, tamoxifen in the treatment of, 171
  - metastatic, pilot study of vinblastine combined with bleomycin in the treatment of, 133
  - multiple myeloma, comparison of two combination chemotherapy regimens for treatment of: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone, 73
  - neuroblastoma
- human, in vitro and in vivo preclinical chemotherapy studies of**, 975
- human, variability in DNA distributions of, after cyclophosphamide**, 1275
- osteosarcoma**
- metastatic, high-dose methotrexate with leucovorin rescue used alone and in combination for, 11
  - primary, high-dose methotrexate with leucovorin rescue used alone and in combination for, 11
- ovarian**
- active third-line chemotherapy with weekly *cis*-diamminedichloroplatinum(II) in: a preliminary report, 1379
  - advanced, *cis*-diamminedichloroplatinum(II) in the treatment of, 1147
  - advanced, hexamethylmelamine, cyclophosphamide, methotrexate, and 5-FU in the treatment of, in patients with and without previous treatment, 323
- pancreatic**
- advanced adenocarcinoma, long-term survival in patients with, 1391
  - phase II study of L-asparaginase in the treatment of, 1359
- prostate, refractory metastatic, tamoxifen in the treatment of**, 813
- rectum, metastatic adenocarcinoma, phase II evaluation of PALA in the treatment of**, 339
- renal cell**
- advanced, methotrexate and citrovorum factor used alone and in combination for, 41
  - advanced, phase II study of tamoxifen in the treatment of, 343
  - metastatic, ifosfamide and mesnun with and without irradiation in the treatment of, 1103
  - metastatic, phase II trial of AMSA in the treatment of, 1009
  - metastatic, phase II trial of Baker's antifol in the treatment of: a Southwest Oncology Group study, 1387
- sarcoma**
- advanced, cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) in the treatment of, 93
  - advanced, phase II evaluation of AMSA in the treatment of, 1129
  - advanced, phase II study in: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP), 655
  - advanced, results of the Royal Marsden Hospital Second Soft Tissue Sarcoma Schedule (STS II) chemotherapy regimen in the management of, 689
  - osteogenic, longitudinal studies of cellular immunity of patients with, during chemoimmunotherapy, 589
  - osteogenic, pulmonary function tests during adjuvant lung irradiation for, 701
- squamous cell**
- advanced recurrent, doxorubicin combined with cyclophosphamide in the treatment of, 1363
  - bleomycin, vincristine, and mitomycin C with or without methotrexate in the treatment of, 943

- testicular  
alone and in combination in the treatment of, 1077  
disseminated nonseminomatous, sequential combination chemotherapy with vinblastine plus bleomycin doxorubicin plus *cis*-diamminedichloroplatinum(II) in the treatment of, 599  
metastatic, probable cure of, treated with sequential therapy (vinblastine and bleomycin followed by *cis*-diamminedichloroplatinum[II], actinomycin D, and vincristine), 553  
prognostic factors in: an approach to identification, 487  
stage III, vinblastine, intermittent bleomycin, and single-dose *cis*-diamminedichloroplatinum(II) in the management of, 381  
staging: a proposed clinical-surgical schema, 669  
transitional cell  
metastatic, of the urinary tract, combination chemotherapy with cyclophosphamide, doxorubicin, and bleomycin in the treatment of, 1011  
of the urinary tract, phase II study of 5-FU and adriamycin in the treatment of, 161  
vaginal, doxorubicin, cyclophosphamide, and 5-FU in the treatment of, 549  
vulvar, advanced or recurrent, squamous cell, bleomycin alone or combined with mitomycin C in the treatment of, 639  
**CAP (cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum[II])**, randomized trial, versus pyrazofurin in a phase II study of advanced sarcoma, 655  
**Cardiomyopathy** *see* Adverse effects, man  
**Cardiotoxicity** *see* Adverse effects, animals; Adverse effects, man  
**Catheter**, right atrial, use of for prolonged iv support in cancer patients, 243  
**CCNU**  
cause of variability in activity of samples of, against P388 leukemia *in vivo*, 987  
combined with melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635  
combined with procarbazine and vincristine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143  
combined with procarbazine and vincristine (PCV 3), modified, in the treatment of malignant brain tumors, 237  
combined with procarbazine, vincristine, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139  
and doxorubicin, compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of small cell bronchogenic cancer, 997  
**Cell culture studies**  
amygdalin (Laetrile), effect on clonogenic cells from human myeloid leukemia lines and normal human marrow, 105  
inhibition by selected anticancer agents of the development of primary cell-mediated immunity against allogeneic tumor cells, 211  
**Cell kinetics**  
effect of doxorubicin on, of 13762 rat mammary tumors and implications for therapy, 293  
epidermal, in hairless mice after bleomycin: perturbations after multiple doses, 1039  
**Cervical cancer** *see* Cancer, cervical  
**Chlorozotocin**  
cholestatic jaundice associated with, 1235  
combined with maytansine, phase II study of, in the treatment of disseminated malignant melanoma, 721  
**Chlorpromazine**, combined with caffeine and methyl-CCNU in the treatment of disseminated melanoma, 151  
**Cholestatic jaundice** *see* Adverse effects, man  
**CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)**, advanced diffuse histiocytic lymphoma treatment with, without maintenance therapy, 649  
**Cisplatin** *see* *cis*-Diamminedichloroplatinum(II)  
**Citrovorum factor**, and methotrexate used alone and in combination chemotherapy for advanced renal cell carcinoma, 41  
**Clinical cancer**  
animal models of cancer immunotherapy: questions of relevance, 481  
application of restricted sequential design in, 399  
basic design considerations, 411  
clinical considerations in the design of, 367  
critical definitions and criteria for evaluation, 469  
designing for nonparametric Bayesian survival analysis using historical controls, 503  
design of phase II clinical trials in cancer using decision theory, 519  
Designs for Clinical Cancer Research, Proceedings of the Symposium on, 363-388  
designs to optimize combined-modality therapy and selection and verification of prognostic factors, 497  
evaluation of toxicity: clinical issues, 457  
evaluation of toxicity: statistical considerations, 463  
operative procedures: is standardization feasible or necessary, 419  
patient heterogeneity in, 405  
perspective of the clinician, 537  
pilot studies and new agent programs of the Eastern Cooperative Oncology Group, 525  
in psychosocial medicine: methodologic and statistical considerations: assessing measurement techniques in psychosocial oncology, 451  
in psychosocial medicine: methodologic and statistical considerations: assessing reliability with equal-appearing interval scales, 445  
in psychosocial medicine: methodologic and statistical considerations: introduction, 441  
quality assurance programs in, 425  
research logic of radiation oncology in combined modality therapy, 473  
selection of prognostic factors, 499  
sequential, in cancer research, 393  
summary views: a statistician's perspective, 533  
use of new biologic agents in clinical immunotherapy, 435

- use of prognostic factors in analysis of historical control studies, 373
- use of prognostic factors in improving the design and efficiency of, in childhood leukemia: a Children's Cancer Study Group report, 381
- CMF (cyclophosphamide, methotrexate, and 5-FU), versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635**
- CMFH (cyclophosphamide, methotrexate, 5-FU, and hydroxyurea), versus high-dose cyclophosphamide in the treatment of stage III non-small cell lung cancer: a randomized trial, 1131**
- Colon cancer** *see* Cancer, colon
- Colorectal cancer** *see* Cancer, colorectal
- 7-Con-O-methylnogarol (7-OMEN)**
- and aclacinomycin, failure to decrease cardiac guanylate cyclase activity, 1127
  - activity of the anthracycline agent (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia, 727
- Corynebacterium parvum**
- combined with doxorubicin and *cis*-diamminedichloroplatinum(II) in the treatment of non-small cell lung cancer, 1367
  - combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
  - enhancement of the antitumor activity of, by appropriate adjustment of dose schedules, 915
- Cyclophosphamide**
- combined with adriamycin and high-dose methotrexate with leucovorin rescue in the treatment of measurable primary or metastatic osteosarcoma, 11
  - combined with adriamycin and vincristine and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65
  - combined with doxorubicin and bleomycin in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001
  - combined with doxorubicin and *cis*-diamminedichloroplatinum(II) (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655
  - combined with doxorubicin and 5-FU in the treatment of carcinoma of the cervix or vagina, 549
  - combined with doxorubicin in the treatment of advanced recurrent squamous cell carcinoma, 1363
  - combined with doxorubicin, vincristine, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649
  - combined with 5-FU, adriamycin, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
  - combined with hexamethylmelamine, methotrexate, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323
  - combined with methotrexate and 5-FU (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635
  - combined with methyl-CCNU and prednisone versus melphalan and prednisone in the treatment of multiple myeloma, 73
  - combined with procarbazine, vincristine, and CCNU (POCC) in the treatment of metastatic malignant melanoma, 139
  - combined with triazinate, doxorubicin, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925
  - combined with vincristine, adriamycin, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 93
  - combined with vincristine and actinomycin D followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689
  - combined with VP-16-213, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135
  - and doxorubicin and *cis*-diamminedichloroplatinum(II), lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311
  - high-dose, versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial, 1181
  - plasma half-life and urinary excretion of, in children, 1061
  - with prednisone, 5-FU, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111
  - variability in DNA distributions of human neuroblastomas after, 1275
- CYVADIC (cyclophosphamide, vincristine, doxorubicin, and DTIC), combination chemotherapy for the treatment of advanced sarcomas, 93**
- D**
- Danazol, in the treatment of advanced breast cancer, 1073**
- 3-Deazauridine, phase I study of, in adults with solid tumors, 1295**
- cis*-Diamminedichloroplatinum(II) (cisplatin)**
- alone and in combination in the treatment of testicular and other malignancies, 1077
  - combined with bleomycin and vinblastine in the treatment of mediastinal germ-cell tumors: complete remission of, 319
  - combined with bleomycin, doxorubicin, and methotrexate (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717
  - combined with bleomycin, vincristine, and mitomycin C (BOMP) in the treatment of advanced cervical cancer, 1005
  - combined with cyclophosphamide and doxorubicin (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655

combined with cyclophosphamide and doxorubicin, lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311  
combined with doxorubicin and *Corynebacterium parvum* in the treatment of non-small cell lung cancer, 1367  
combined with triazinate, cyclophosphamide, and doxorubicin, phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925  
and doxorubicin, sequential combination chemotherapy with vinblastine and bleomycin in disseminated non-seminomatous testicular cancer, 599  
high-dose, with fluid- and mannitol-induced diuresis in the treatment of advanced lung cancer: phase II clinical trial, 1341  
infiltration, cellulitis and fibrosis due to, 1162  
nephrotoxicity of, as measured by urinary  $\beta$ -glucuronidase, 1083  
nerve conduction studies in patients treated with: a preliminary report, 1119  
phase I study of, administered as a constant 5-day infusion, 905  
quantitative changes in, speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results, 123  
renal handling of, 1223  
a role of, in the treatment of squamous cell lung cancer, 87  
selective inhibition of the nephrotoxicity of, by WR-2721 without altering its antitumor properties, 57  
single-dose, combined with vinblastine and intermittent bleomycin in the management of stage III testicular cancer, 331  
toxicity and antitumor activity, effect of sodium thiosulfate on, in L1210 leukemia, 611  
in the treatment of advanced ovarian cancer, 1147  
in the treatment of esophageal carcinoma, 709  
weekly, active third-line chemotherapy in ovarian carcinoma: a preliminary report, 1379  
with and without ICRF-159 in the treatment of non-Hodgkin's lymphoma, 301  
**Dianhydrogalactitol**, and neural tumors: as in vitro, in vivo preclinical evaluation, 1287  
**Diglycoaldehyde (Inox)**  
phase II evaluation of, in the treatment of children with acute leukemia: a Children's Cancer Study Group report, 625  
in the treatment of advanced adult acute leukemia: a Southwest Oncology Group study, 985  
**Dimethylhydrazine**, -induced intestinal tumors, indomethacin treatment of rats with, 1323  
**DON (6-diazo-5-oxo-norleucine)**, phase I study of, 1247  
**Doxorubicin** see Adriamycin  
**DTIC**  
combined with cyclophosphamide, vincristine, and adriamycin (CYVADIC) in the treatment of advanced sarcomas, 98  
photosensitivity reaction following DTIC administration: report of two cases, 725  
in the treatment of metastatic malignant melanoma: a simplified dose schedule, 1123

**Dyskinesia, respiratory** see Adverse effects, man

## E

**Emesis** see Adverse effects, man  
**4'-Epi-doxorubicin**, studies on the comparative distribution and biliary excretion of, with doxorubicin, in mice and rats, 897  
**Esophageal cancer** see Cancer, esophageal

## F

**Fluorodopan**, phase II study of, in the treatment of advanced colorectal cancer, 697  
**Fluoxymesterone**, in the treatment of advanced breast cancer: a controlled clinical trial, 117  
**Florafur**, phase II study of, in previously treated squamous cell cancers of the head and neck, 713  
**5-FU (5-fluorouracil)**  
combined with adriamycin, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157  
combined with adriamycin, phase II study of, in the treatment of transitional cell carcinoma of the urinary tract, 161  
combined with Baker's antifol and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247  
combined with cyclophosphamide and methotrexate (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635  
combined with doxorubicin and cyclophosphamide in the treatment of carcinoma of the cervix or vagina, 549  
combined with hexamethylmelamine, cyclophosphamide, and methotrexate in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323  
combined with mitomycin C, effects of chemotherapy with, on pancreatic functions in patients with gastric cancer, 1151  
combined with thymidine, clinical pharmacologic effects of, 1169  
combined with triazinate, ICRF-159, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143  
combined with vincristine and mitomycin C in the treatment of extensive adenocarcinoma of the lung, 1241  
combined with vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371  
high-dose, and intermediate-dose methotrexate, effectiveness of, as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon, 829  
intra-arterial infusion of, review of responses, 31

with prednisone, cyclophosphamide, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111  
versus ICRF-159, phase III study of, in the treatment of advanced metastatic colorectal carcinoma, 1047

## G

**Gastric cancer** *see* Cancer, gastric  
**Gentamicin**, and irradiation, effect of, on the toxicity of high-dose methotrexate in rats, 989  
**Germ-cell cancer** *see* Cancer, germ-cell

## H

**Head and neck cancer** *see* Cancer, head and neck  
**Hepatic artery chemotherapy**, radionuclide angiography to predict response to, 1217  
**Hepatic necrosis** *see* Adverse effects, man  
**Hepatotoxicity** *see* Adverse effects, man  
**Hexamethylmelamine**  
combined with cyclophosphamide, methotrexate, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323  
respiratory dyskinesia associated with, 355  
**HCFU (1-hexylcarbamoyl-5-fluorouracil)**, phase I study of, administered orally: an HCFU clinical study group report, 861  
**1-Hexylcarbamoyl-5-fluorouracil** *see* HCFU  
**Hycanthone**, hepatotoxicity of, in patients with metastatic breast cancer, 929  
**Hydrocortisone**, combined with vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, and 5-FU in the treatment of advanced cutaneous T-cell lymphomas, 1371  
**9-Hydroxyellipticine**, and 2-methyl-9-hydroxyellipticinium acetate, metabolism and disposition studies of, in animals, 879  
**7-Hydroxymethotrexate**, and methotrexate: serum level monitoring by high-pressure liquid chromatography, 165  
**Hydroxyurea**  
combined with cyclophosphamide and 5-FU versus high-dose cyclophosphamide in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized study, 1131  
infusion, synchronization of L1210 leukemia with, and the effect of subsequent pulse dose chemotherapy, 81  
**Hypernephroma**, metastatic, phase II trial of AMSA in the treatment of, 183  
**Hyperthermia**  
local, distribution of doxorubicin in mice under conditions of, which improve systemic drug therapy, 203  
malignant, Burkitt's lymphoma: tumor lysis following, 327

## I

**ICRF-159**  
combined with cis-diamminedichloroplatinum(II) in the treatment of non-Hodgkin's lymphoma, 301  
combined with triazinate, 5-FU, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143  
pharmacokinetics of, in the cerebrospinal fluid of sub-human primates, 734  
randomized clinical trial comparing two dose regimens of, in refractory malignant lymphomas, 1355  
versus 5-FU, phase III study of, in the treatment of advanced metastatic colorectal carcinoma, 1047  
preclinical toxicologic evaluation of, in dogs, 1211

**Ifosfamide**  
combined with doxorubicin in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study, 869  
combined with mesnun with and without irradiation, in the treatment of renal cancer, 1103  
combined with methotrexate and vincristine as secondary treatment for patients with malignant lymphoma, 933  
**Immunotherapy**  
levamisole, and polychemotherapy in advanced breast cancer, 65  
longitudinal studies of cellular immunity of patients with osteogenic sarcoma during, 589

**IMPY**  
clinical pharmacology of, by radioimmunoassay, 1253  
clinical toxic effects of, with relevant pharmacokinetic parameters, 251  
phase I clinical trial of, 1153  
preclinical toxicologic study of, in mice, dogs, and monkeys, 1081

**Indometacin**, treatment of rats with dimethylhydrazine-induced intestinal tumors, 1323  
**Inox** *see* Diglycoaldehyde

## L

**Lactate dehydrogenase virus**, infection of murine tumors: no effect on response to chemotherapy, 1161  
**Laetile (amygdalin)**

effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow, 105  
trials as an example: ethics and designs, 363

**Leucovorin**  
factor, combined with vincristine, doxorubicin, bleomycin, methotrexate, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371

rescue, leukoencephalopathy following high-dose iv methotrexate chemotherapy with, 1261  
rescue, with high-dose methotrexate alone or in combination with adriamycin and cyclophosphamide in the treatment of measurable primary or metastatic osteosarcoma, 11

**Leukemia**  
acute

- adult advanced, diglycoaldehyde in the treatment of: a Southwest Oncology Group study, 985  
 adult, previously treated, doxorubicin and ifosfamide in the treatment of: a Southwest Oncology Group pilot study, 869  
 childhood, phase II evaluation of diglycoaldehyde (Inox) in, a Children's Cancer Study Group report, 625  
 lymphocytic, childhood, use of prognostic factors in improving the design and efficiency of clinical trials in: a Children's Cancer Study Group report, 381  
 refractory, sequential combination of methotrexate and L-asparaginase in the treatment of, 939  
 treatment of, during pregnancy: presentation of nine cases, 679
- Levamisole**, immunotherapy, and polychemotherapy in advanced breast cancer, 65
- Lewis lung cancer** see Tumor systems, animals
- L1210 leukemia** see Tumor systems, animals
- Lung cancer** see Cancer, lung
- Lymphoma** see Cancer, lymphoma

## M

### **Maytansine**

combined with chlorozotocin, phase II study of, in the treatment of disseminated malignant melanoma, 721  
 minimal single-agent activity of, in refractory breast cancer: a Southwest Oncology Group study, 675  
 phase II study of, in the treatment of advanced lymphomas: an Eastern Cooperative Oncology Group pilot study, 1115  
 response to, in a patient with malignant thymoma, 193

**Melanoma** see Cancer, melanoma

### **Melphalan**

combined with CCNU, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635  
 combined with doxorubicin and vincristine in the treatment of advanced breast cancer, 1015

combined with prednisone versus methyl-CCNU, cyclophosphamide, and prednisone in the treatment of multiple myeloma, 73

distribution and elimination of, in rats and monkeys and distribution in tumors of mice bearing L1210 or P388 leukemias sensitive and resistant to this agent, 643  
 the first 25 years, 559

intra-arterial infusion of, review of responses, 31  
 oral, anaphylaxis due to, 731

**6-Mercaptopurine**, selective protection of cells from, by adenosine: biochemical approaches to the enhancement of antitumor drug selectivity, 1347

**Mesna**, combined with ifosfamide with and without irradiation, in the treatment of renal cancer, 1103

### **Methotrexate**

and L-asparaginase, sequential combination of, in the treatment of refractory acute leukemia, 939

and citrovorum factor used alone and in combination chemotherapy for advanced renal cell carcinoma, 41 combined with bleomycin, doxorubicin, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717 combined with CCNU, melphalan, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with cyclophosphamide and 5-FU (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with cyclophosphamide, 5-FU, and hydroxyurea (CMFH) versus high-dose cyclophosphamide in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial, 1131

combined with 5-FU, Adriamycin, cyclophosphamide, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157

combined with hexamethylmelamine, cyclophosphamide, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323

combined with ifosfamide and vincristine as secondary treatment for patients with malignant lymphoma, 933 combined with vincristine, doxorubicin, bleomycin, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371 and doxorubicin, given after combination of vincristine, actinomycin D, and cyclophosphamide in the treatment of advanced sarcoma, 689

high-dose, effect of gentamicin and irradiation on the toxicity of, in rats, 989

high-dose iv, leukoencephalopathy following, with leucovorin rescue, 1261

high-dose, phase II study of, in the treatment of non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study, 1017

high-dose, with leucovorin rescue, used alone and in combination for measurable primary or metastatic osteosarcoma, 11

and 7-hydroxymethotrexate: serum level monitoring by high-performance liquid chromatography, 165

intermediate-dose, and high-dose 5-FU, effectiveness of, as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon, 829

intra-arterial infusion of, review of responses, 31

with prednisone, cyclophosphamide, 5-FU, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111

### **Methyl-CCNU**

combined with Baker's antifol and 5-FU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247

combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma, 73

combined with triazine, ICRF-159, and 5-FU in the treatment of advanced colorectal cancer, 1143  
given alone or combined with chlorpromazine and caffeine in the treatment of disseminated melanoma, 151  
**2-Methyl-9-hydroxyellipticinium acetate**, and 9-hydroxyellipticine, metabolism and disposition studies of, in animals, 879  
**Metoprine**, phase I trial of, in patients with advanced cancer, 951  
**Metronidazole**, high-dose: pharmacokinetics and bioavailability using an iv preparation and application of its use as a radiosensitizer, 1087  
 **$\beta$ 2-Microglobulin**, urinary, increased after cancer chemotherapy, 581  
**Misonidazole**  
effect of hepatic microsomal enzyme inducers on the metabolism of, in rats, 275  
effect of, on human granulopoietic stem cells, 1097  
the 2-nitroimidazole, skin rashes associated with the administration of, 263  
and phenytoin: possible metabolic interaction, 155  
phenytoin sodium-induced alterations in the pharmacokinetics of, in the dog, 360  
**Mitomycin C**  
combined with bleomycin and vincristine with or without methotrexate in the treatment of squamous cell carcinoma, 943  
combined with bleomycin in the treatment of advanced or recurrent squamous cell carcinoma of the vulva, 639  
combined with bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study, 1139  
combined with bleomycin, vincristine, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005  
combined with 5-FU and vincristine in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung, 1241  
combined with 5-FU, effects of chemotherapy with, on pancreatic functions in patients with gastric cancer, 1151  
topical therapy, phase I-II study of, in the treatment of low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225  
**Multiple myeloma** *see* Cancer, multiple myeloma

## N

**Nabilone**, and prochlorperazine, double-blind comparison of the antiemetic effects of, on chemotherapy-induced emesis, 219  
**Nephrotoxicity** *see* Adverse effects, animals; Adverse effects, man  
**Neuro conduction studies**, in patients treated with *cis*-diamminedichloroplatinum(II), 1119  
**Neuroblastoma** *see* Cancer, neuroblastoma  
**Neurotoxicity** *see* Adverse effects, animals

## O

**7-OMEN** *see* 7-Con-O-methylnogarol  
**Osteosarcoma** *see* Cancer, osteosarcoma  
**Ovarian cancer** *see* Cancer, ovarian

## P

### PALA

initial clinical study with, in patients with advanced cancer, 617  
peripheral leukocytes as indicators of the enzymatic effects of, on human L-aspartate transcarbamoylase activity, 967  
phase I clinical study of, 285, 1301  
phase I trial of, 1067  
phase II evaluation of, in the treatment of advanced colorectal carcinoma, 349  
phase II evaluation of, in the treatment of metastatic adenocarcinoma of the colon or rectum, 339  
phase II evaluation of, in the treatment of non-small cell carcinoma of the lung, 705  
**Pancreatic cancer** *see* Cancer, pancreatic  
**PCV 3 (procarbazine, CCNU, and vincristine)**, modified, in the treatment of malignant brain tumors, 237  
**Pentamethylmelamine**  
early clinical trial of a 1-day intermittent schedule for, 993  
phase I study of, 1319  
phase I trial of, in patients with previous treated malignancies, 1335  
a sensitive and specific assay for, in plasma: applicability to clinical studies, 99

**Pepleomycin**, and tallysomycin A, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs in mice bearing Lewis lung carcinoma and B16 melanoma, 659

**Pericarditis** *see* Adverse effects, man  
**Peritoneovenous shunt**, complications of, for malignant ascites, 305  
**Pharmacokinetics**  
and bioavailability using an iv preparation and application of high-dose methotrexate's use as a radiosensitizer, 1087  
clinical toxic effects of IMPY with relevant pharmacokinetic parameters, 251  
early phase, of doxorubicin in plasma of cancer patients during single- or multiple-drug therapy, 845  
of ICRF-187 in the cerebrospinal fluid of subhuman primates, 734  
intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses, 31  
of misomidazole in the dog, phenytoin sodium-induced alterations in the, 360  
studies on the metabolism and, of tamoxifen in normal volunteers, 761  
of vinblastine-loaded platelets utilized in the treatment of platelet-phagocytizing tumors, 1227

### **Phase I studies**

- of AMSA by a weekly iv dose schedule, 58
- of *cis*-diamminedichloroplatinum(II) administered as a constant 5-day infusion, 905
- clinical study, of PALA, 285
- of 3-deazauridine in the treatment of adults with solid tumors, 1295
- of DON, 1247
- of HCFU (a new antitumor drug), administered orally: an HCFU clinical study group report, 861
- of IMPY, 1153
- of metoprine in patients with advanced cancer, 951
- of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225
- of PALA, 1067, 1301
- of pentamethylmelamine, 1319
- of pentamethylmelamine in patients with previously treated malignancies, 1335
- and preliminary phase II observations of high-dose intermittent 6-thioguanine, 1109
- of spirogermanium, 1051

### **Phase II studies**

- abbreviated, of thalcarpine, 1389
- in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP), 655
- of AMSA in the treatment of advanced colorectal cancer, 1149
- of AMSA in the treatment of advanced non-Hodgkin's lymphoma, 1157
- of AMSA in the treatment of advanced sarcoma, 1129
- of AMSA in the treatment of metastatic hypernephroma, 183
- of AMSA in the treatment of metastatic lung cancer, 1383
- of AMSA in the treatment of metastatic renal cell carcinoma, 1009
- of AMSA in the treatment of non-small cell lung cancer, 345
- of L-asparaginase in the treatment of pancreatic carcinoma, 1359
- of Baker's antifol in the treatment of metastatic renal cell carcinoma: a Southwest Oncology Group study, 1387
- of the combination of triazine, cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung, 925
- of diglycoaldehyde (Inox) in children with acute leukemia: a Children's Cancer Study Group report, 625
- evaluation of agents in current use in the treatment of brain tumors, 1179
- of fluorodopan in the treatment of advanced colorectal cancer, 697
- of flotarafur in the treatment of previously treated squamous cell cancers of the head and neck, 713
- of 5-FU and adriamycin in transitional cell carcinoma of the urinary tract, 161
- of high-dose *cis*-diamminedichloroplatinum(II) with fluid- and mannitol-induced diuresis in the treatment

of advanced lung cancer, 1341

- of high-dose methotrexate in the treatment of non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study, 1017
- of maytansine and chlorozotocin in the treatment of disseminated malignant melanoma, 721
- of maytansine in the treatment of advanced lymphomas: an Eastern Cooperative Oncology Group pilot study, 1115
- of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225
- of PALA in the treatment of advanced colorectal carcinoma, 349
- of PALA in the treatment of metastatic adenocarcinoma of the colon or rectum, 339
- of PALA in the treatment of non-small cell carcinoma of the lung, 705
- preliminary, and phase I observations of high-dose intermittent 6-thioguanine, 1109
- of tamoxifen in the treatment of advanced renal cell carcinoma, 343
- of tamoxifen in the treatment of disseminated malignant melanoma, 199
- of 6-thioguanine in the treatment of metastatic breast cancer, 191
- of triazine in the treatment of metastatic lung cancer, 1057
- use of a clinical tumor panel and overview of current resources and studies, 1
- of vindesine in the treatment of advanced head and neck cancer, 1141
- of vindesine in the treatment of advanced breast cancer, 693
- of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors, 1001
- of vindesine in the treatment of malignant melanoma, 179
- of VM-26 in the treatment of adult malignancies, 147

### **Phase III studies**

- evaluation of agents in current use in the treatment of brain tumors, 1179
- of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma, 1047

**L-Phenylalanine mustard (L-PAM)** *see* Melphalan

**Phenytoin**, and misonidazole: possible metabolic interaction, 155

**Photosensitivity** *see* Adverse effects, man

**Piperazinedione**, extravasation, severe skin necrosis produced by, 1392

**P388 leukemia** *see* Tumor systems, animals

**POCC (procarbazine, vincristine, CCNU, and cyclophosphamide)**, in the treatment of metastatic malignant melanoma, 139

**Prednisone**

combined with CCNU, melphalan, and methotrexate (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with cyclophosphamide, doxorubicin, and vincristine (CHOP) in the treatment of advanced dif-

fused histiocytic lymphoma, without maintenance therapy, 649  
combined with melphalan versus methyl-CCNU, cyclophosphamide, and prednisone in the treatment of multiple myeloma, 73  
combined with methyl-CCNU and cyclophosphamide versus melphalan and prednisone in the treatment of multiple myeloma, 73  
combined with VM-26, doxorubicin, and bleomycin as a secondary treatment of malignant lymphoma, 335  
combined with VP-16-213, cyclophosphamide, doxorubicin, and vincristine in the treatment of non-Hodgkin's lymphomas, 1135  
with cyclophosphamide, 5-FU, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111  
**Price-Hill regimen** (vincristine, bleomycin, methotrexate, hydrocortisone, 5-FU, and leucovorin), in the treatment of advanced squamous cell carcinoma of the head and neck, 187  
**Procarbazine**  
and CCNU, doxorubicin, and vincristine, compared to CCNU and doxorubicin in the treatment of small cell bronchogenic cancer, 997  
combined with CCNU and vincristine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143  
combined with CCNU and vincristine (PCV 3), modified, in the treatment of malignant brain tumors, 237  
combined with vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139  
**Prochlorperazine**, and nabilone, double-blind comparison of the antiemetic effects of, on chemotherapy-induced emesis, 219  
**Prostatic cancer** see Cancer, prostatic  
**Pseudomonas** vaccine, combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, and *Corynebacterium parvum* in the treatment of metastatic breast cancer, 157  
**Pyrazofurin**, randomized trial of, versus combination of cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP): phase II study in advanced sarcoma, 655

## R

**Radiation therapy**  
curative, for localized diffuse histiocytic lymphoma, 175  
and gentamicin, effect of, on the toxicity of high-dose methotrexate in rats, 989  
treatment of metastatic renal cancer with ifosfamide and mesnium with and without, 1103  
whole-brain, results of, for metastases from small cell carcinoma of the lung, 957  
**Radioimmunoassay**, clinical pharmacology of IMPY by, 1253  
**Radionuclide angiography**, to predict response to hepatic artery chemotherapy, 1217

**13762 Rat mammary tumor** see Tumor systems, animals  
**Rectal cancer** see Cancer, rectal  
**Renal cell cancer** see Cancer, renal cell  
**Ricin**, combined with doxorubicin in the treatment of L1210 mouse leukemia, 1375

## S

**Sarcoma** see Cancer, sarcoma  
**Selenium**, and vitamin E protection, evaluation of, against chronic doxorubicin toxicity in rabbits, 315  
**Sodium thiosulfate**, effect of, on *cis*-diamminedichloroplatinum(II) toxicity and antitumor activity in L1210 leukemia, 611  
**Spirogermanium**  
phase I clinical trial of, 1051  
toxicity of, in mice and dogs after iv or im administration, 1207  
**Spirohydantoin mustard**, recovery from potentially lethal damage induced by, on 9L cells in vitro, 889  
**Squamous cell cancer** see Cancer, squamous cell

## T

**Tallysomycin A**, and pepleomycin, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs in mice bearing Lewis lung carcinoma and B16 melanoma, 659  
**Tamoxifen**  
antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function, 779  
clinical pharmacology of, in patients with breast cancer: comparison of traditional and loading-dose schedules, 765  
estrogen and progesterone receptors and, in malignant melanoma, 819  
estrogen-receptor binding and biologic activity of, and its metabolites, 741  
estrogen receptors and antiestrogen therapy in selected human solid tumors, 797  
an overview of recent studies in the field of oncology, 775  
pharmacology of, in laboratory animals, 745  
phase II study of, in the treatment of advanced renal cell carcinoma, 343  
phase II study of, in the treatment of disseminated malignant melanoma, 199  
studies on the metabolism and pharmacokinetics of, in normal volunteers, 761  
therapy in premenopausal patients with metastatic breast cancer, 787  
in the treatment of advanced breast cancer: a controlled clinical trial, 117  
in the treatment of advanced endometrial adenocarcinoma, 805  
in the treatment of metastatic malignant melanoma, 171

- in the treatment of refractory metastatic carcinoma of the prostate, 813  
use of, in advanced male breast cancer, 801
- Testicular cancer** *see* Cancer, testicular
- Thalicarpine**, abbreviated phase II trial of, 1389
- 6-Thioguanine**  
high-dose intermittent, phase I and preliminary phase II observations of, 1109  
phase II trial of, in the treatment of metastatic breast cancer, 191  
selective protection of cells from, by adenosine: biochemical approaches to the enhancement of antitumor drug selectivity, 1347
- Thioproline**, pharmacologic and toxicologic evaluation of: a proposed nontoxic inducer of reverse transformation, 837
- Thymidine**  
arrest and synchrony of cellular growth in vivo, 1307  
combined with 5-FU, clinical pharmacologic effects of, 1169
- Thymoma**, malignant, response to maytansine in a patient with, 193
- Transitional cell cancer** *see* Cancer, transitional cell
- Triazinate**  
combined with cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925  
combined with ICRF-159, 5-FU, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143  
phase II evaluation of, in the treatment of metastatic lung cancer, 1057
- Tumor systems, animals**  
B16 melanoma, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomyein A in, 659  
Lewis lung carcinoma  
effect of microbial fractions and vehicle on the survival of mice bearing, 1329  
relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomyein A in, 659
- L1210 leukemia  
activity of the anthracycline agent, 7-con-*O*-methylngarol (7-OMEN), administered orally to mice bearing, 727  
combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo, 231  
distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing L1210 leukemia sensitive and resistant to this agent, 643  
effect of sodium thiosulfate on *cis*-diamminedichloroplatinum(II) toxicity and antitumor activity in, 611  
strongly synergistic combination of doxorubicin and ricin in, 1375  
synchronization of, with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy, 81
- P388 leukemia  
activity of the anthracycline agent, 7-con-*O*-methylngarol (7-OMEN), administered orally to mice bearing, 727  
cause of variability in activity samples of CCNU against, in vivo, 987  
distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing P388 leukemia sensitive and resistant to this agent, 643  
13762 rat mammary tumor, effect of doxorubicin on the cell kinetics of, and implications for therapy, 298

## U

- Urinary  $\beta$ -glucuronidase**, nephrotoxicity of *cis*-diamminedichloroplatinum(II) as measured by, 1083


## V

- Vaginal cancer** *see* Cancer, vaginal
- Vinblastine**  
and bleomycin, sequential combination chemotherapy with doxorubicin and *cis*-diamminedichloroplatinum(II) in disseminated nonseminomatous testicular cancer, 599  
combined with bleomycin and followed sequentially by *cis*-diamminedichloroplatinum(II), actinomycin D, and vincristine in the treatment of metastatic testicular cancer, 553  
combined with bleomycin, coronary artery disease after treatment with, 1159  
combined with bleomycin in the treatment of metastatic melanoma, 133  
combined with *cis*-diamminedichloroplatinum(II) and bleomycin in the treatment of mediastinal germ-cell tumors: complete remission of, 319  
combined with intermittent bleomycin and single-dose *cis*-diamminedichloroplatinum(II) in the management of stage III testicular cancer, 331  
given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer, 279  
-loaded platelets, pharmacokinetics of, utilized in the treatment of platelet-phagocytizing tumors, 1227
- Vincristine**  
and CCNU, doxorubicin, and procarbazine, compared to CCNU and doxorubicin in the treatment of small cell bronchogenic cancer, 997  
combined with actinomycin D and cyclophosphamide followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689  
combined with adriamycin and cyclophosphamide and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65  
combined with bleomycin and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma, 943

- combined with bleomycin, mitomycin C, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005  
combined with CCNU and procarbazine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143  
combined with cyclophosphamide, adriamycin, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 98  
combined with cyclophosphamide, doxorubicin, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649  
combined with doxorubicin, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371  
combined with 5-FU and mitomycin C in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung, 1241  
combined with ifosfamide and methotrexate as secondary treatment for patients with malignant lymphoma, 933  
combined with melphalan and doxorubicin in the treatment of advanced breast cancer, 1015  
combined with procarbazine and CCNU (PCV 3), modified in the treatment of malignant brain tumors, 237  
combined with procarbazine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139  
combined with VP-16-213, cyclophosphamide, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135
- induced orthostatic hypotension: a prospective clinical study, 359  
with prednisone, cyclophosphamide, 5-FU, and methotrexate, used sequentially with endocrine therapy in the treatment of metastatic breast cancer, 111
- Vindesine**  
initial clinical study with: tolerance to weekly iv bolus and 24-hour infusion, 25  
phase II evaluation of, in the treatment of breast cancer, 693  
phase II trial of, in the treatment of advanced head and neck cancer, 1141  
phase II trial of, in the treatment of malignant melanoma, 179
- Vitamin E**, and selenium protection, evaluation of, against chronic doxorubicin toxicity in rabbits, 315
- VM-26**  
combined with doxorubicin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma, 335  
phase II study of, in adult malignancies, 147
- VP-16-213**, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135
- Vulvar cancer** *see* Cancer, vulvar

## W

- WR-2721**, selective inhibition of the nephrotoxicity of *cis*-diamminedichloroplatinum(II) by, without altering its antitumor properties, 57



## Author Index

### A

- Abbruzzi R, 873  
Adam HK, 761  
Ahmann DL, 199, 721  
Ahmed M, 353  
Aisner J, 1009, 1335, 1392  
Alavi J, 343  
Albo V, 381  
Allalunis MJ, 1097  
Allen JC, 1261  
Allen KE, 745  
Al-Sarraf M, 161, 713  
Amadori S, 939  
Arbes H, 41  
Ardalan B, 967  
Argy WF, 1083  
Armitage JO, 649  
Aroney RS, 1011  
Asty CL, 915  
Aviles A, 679  
Bhakoo HS, 819  
Bhatia PS, 1235  
Bickers JN, 869  
Bisel HF, 721  
Bjornsson S, 1367  
Blom J, 1135  
Bloomfield CD, 175, 1135  
Blum RH, 1067  
Blumenschein GR, 157, 279  
Boden JA, 1161  
Bodey GP, Sr, 93, 157, 285, 629, 909, 929, 933, 1253, 1295  
Bondu H, 1341  
Bonnell S, 1363  
Bonnet JD, 247  
Bono VH, Jr, 1  
Bosl GJ, 331, 487  
Bottomley R, 93, 869  
Bowles D, 11  
Boyd MR, 99  
Bracken RB, 225  
Braun DW, Jr, 219  
Braunschweiger PG, 293  
Brenner DE, 1392  
Breslow N, 497  
Brodovsky H, 343, 813  
Broggini M, 845, 897  
Brotman R, 425  
Browman GP, 231  
Brown BW, Jr, 499  
Brown NS, 1253  
Brown RK, 559, 643  
Brunner KW, 335  
Bryant BM, 689  
Bukowski RM, 1387  
Bull FE, 943  
Bull JM, 1015  
Burgess AM, Jr, 285  
Burgess MA, 909, 1295  
Burgess ME, 93  
Buzdar AU, 157, 373  
Byar D, 469  
Byhardt RW, 957

### B

- Bach BK, 801  
Bachur N, 123  
Baker LH, 93, 1139  
Baker SR, 943  
Banerjee TK, 191  
Barbieri B, 873  
Barlogie B, 1295  
Barlow JJ, 549, 1379  
Barnett M, 765  
Bate man JR, 47, 981  
Battersby LA, 775, 801  
Baumgartner G, 41  
Becherini JO, 73  
Beck TM, 725  
Begg CB, 1355  
Belt RJ, 1235  
Benedict WF, 975, 1275  
Benigni A, 873  
Benjamin RS, 93, 629, 1253, 1295  
Bennett JM, 525  
Bennett WM, 921  
Berenzweig M, 717, 1143  
Beretta G, 353  
Bernheim J, 1341  
Bertrand M, 889  
Beutler E, 243

### C

- Cabanillas F, 933  
Cable R, 1227  
Calanog A, 1005

Calman KC, 797  
Camacho FJ, 179, 693  
Campbell M, 713  
Canellos GP, 1067, 1147  
Canfell C, 165  
Caracandas J, 1367  
Carcelen A, 701  
Carceres E, 701  
Carlson M, 819  
Carmo-Pereira J, 143  
Carr B, 1283  
Carroll DS, 349, 1149  
Carter CJ, 629  
Carter SK, 367  
Casadio M, 1131  
Casper ES, 345, 705, 1247, 1301  
Cassady JR, 963  
Catalano RB, 1047  
Cavagnaro F, 73  
Chahinian P, 193  
Chan RC, 989  
Charles LM, Jr, 1  
Chen H-SG, 31  
Cheng E, 1141  
Chester A, 1001  
Child JA, 581  
Chillar RK, 243  
Chism VT, 1329  
Chiutien DF, 1, 1335  
Chlebowksi RT, 47, 981  
Cho E-S, 257  
Chung HS, 975  
Claudon DB, 419  
Clausen OPF, 1039  
Coakley AJ, 737  
Coccia P, 381  
Cohen MH, 151  
Colombo T, 897  
Coltman C, Jr, 356  
Come SE, 1147, 1217  
Comis R, 1227  
Connors TA, 1160  
Coombes RC, 1073  
Cooney DA, 967  
Corder MP, 301, 649, 1389  
Cormier WJ, 655  
Costa RO, 143  
Cowan DH, 1123  
Cowan JD, 1119  
Cox DR, 533  
Cox JD, 957  
Creagan ET, 87, 199, 311, 721, 925, 993, 1057, 1383  
Crooke ST, 225  
Crowley J, 191  
Culo F, 57  
Currie VE, 693, 951  
Cysyk RL, 203

## D

Dalley DN, 1011  
Danon YL, 1275

Dat-Xuong N, 879  
Davey F, 1227  
Davis HL, Jr, 507  
Davis S, 685, 709  
Davis TE, 191  
Dearnaley D, 1073  
DeCosse JJ, 419  
Deen DF, 889  
Defuria MD, 225  
De Jager R, 1341  
De Laurentis C, 939  
Deneffrio JM, 193, 1153  
Denes AE, 1109  
DeSimone P, 1359  
DeWys W, 669  
DiBella NJ, 359  
Dick FR, 649  
Dierckx P, 1341  
Diggs CH, 339  
Dillman RO, 139  
Di Marco AR, 1131  
Dische S, 263  
Dix CJ, 745  
Doeden D, 1061  
Dombernowsky P, 635  
Donegan WL, 419  
Donelli MG, 845, 873, 897  
D'Orsi CJ, 1217  
Drapkin R, 1367  
Dunbar J, 549  
Duncan G, 643  
Dutcher JS, 99

## E

Eagan RT, 87, 655, 925, 993, 1057, 1383  
Earhart RH, 943  
Edelson RL, 1371  
Edmonson JH, 655, 721  
Edwards MS, 237, 1179  
Egan EM, 1307  
Egorin M, 123  
Ehrke MJ, 211  
Elashoff R, 411  
Ellington OB, 243  
Elliott TE, 649, 1389  
Ellison NM, 363  
Elson D, 356  
Engstrom PF, 1047  
Ensminger WD, 943, 1217, 1307  
Eppolito C, 211  
Epstein J, 1347  
Epstein MB, 1275  
Erik-Johnsson J, 639  
Erlichman C, 967  
Ersboll J, 1135  
Ervin TJ, 1067  
Ettinger DS, 1017  
Evans WE, 11  
Ewing SL, 997

**F**

- Fabian C, 765  
Fahey JL, 243  
Falkson G, 191, 358  
Fantone JC, 1023  
Farbstein M, 243  
Feig S, 1077  
Feldstein ML, 445  
Ferrans VJ, 315  
Ferremans W, 1341  
Finklestein J, 625  
Fisher WB, 327  
Fitzpatrick A, 1227  
Fleming GHA, 243  
Fleming JJ, 581  
Fleming TR, 87, 1057  
Fodstad Ø, 1375  
Fong K-LL, 1253  
Ford HT, 1073  
Fosså SD, 1103  
Fraile RJ, 1139  
Fraley EE, 331, 487  
Frei E, III, 1307  
Freireich EJ, 285, 629, 1253  
Frenning DH, 997, 1159  
Frizzera G, 175  
Frytak S, 87, 721, 925, 1057, 1383  
Fujii M, 1151  
Furner RL, 559

**G**

- Gangji D, 155  
Garrett S, 1109  
Gauci L, 193  
Gazet JC, 1073  
Gehan EA, 373  
George SL, 393  
Ginsberg S, 1227  
Glatstein E, 539  
Gleiser CA, 989  
Glick JH, 343, 813, 1115, 1355  
Glicksman AS, 425  
Golbey RB, 705, 1129  
Goldberg RS, 1319  
Golde DW, 105  
Goldhirsch A, 335  
Goldman A, 487  
Goodnight JE, 1077  
Gormley P, 123, 734  
Gouyette A, 879  
Gralla RJ, 219, 345, 349, 705, 1129, 1301  
Gram TE, 659  
Green AA, 11  
Green MR, 139  
Green SJ, 199  
Greenberg DB, 355  
Greenspan EM, 25

- Greenwald EH, 1005  
Griffin JP, 1319  
Griffiths CT, 1147  
Gross JF, 31  
Gutterman JU, 157

**H**

- Haas CD, 1235  
Hacker MP, 837  
Haq MM, 909, 929  
Hahn RG, 655, 721  
Hajdu E, 1287  
Hanjani P, 1363  
Hammond D, 381, 625  
Hansen MM, 1135  
Harkrader RJ, 1347  
Harris D, 343, 813, 1115  
Hart NE, 725  
Hart RD, 617  
Harvey HA, 731  
Havsteen H, 635  
Heilbrun LK, 247  
Heinz R, 41  
Helson J-L, 1287  
Helson L, 1287  
Henderson ES, 1367  
Henriques E, 143  
Henry MC, 855, 1031, 1207, 1211  
Hersh EM, 157  
Herson J, 463  
Hewlett JS, 869  
Higby D, 1367  
Higgins GR, 625  
Hilgers R, 1139  
Hill DL, 643  
Ho DHW, 629, 1253  
Holland JF, 25, 617, 1169  
Hoogstraten B, 537  
Horten B, 1261  
Hortobagyi GN, 157, 279  
Horton C, 139  
Horton J, 1115  
Hoshino T, 889  
Hoth D, 1051  
Houghton A, 345, 705  
Houghton DC, 921  
Howarth C, 11  
Howell SB, 611  
Hueser J, 47  
Humphreys J, 1073  
Hussein K, 869

**I**

- Ihde DC, 539  
Ingle JN, 87, 199, 925, 1057, 1383  
Irwin LE, 981  
Isaacs H, Jr, 975

**J**

- Jackson RC, 1847  
Jacobs C, 1223  
Jacobs EM, 47, 669  
Jaffrey IS, 193, 1391  
Jait C, 73  
Jayaram HN, 967  
Jensen-Akula MS, 1  
Jiang N-S, 199  
Johnson DE, 225  
Johnson K, 487  
Johnson RK, 1067  
Jones NF, 419  
Jones RB, 99  
Jones SE, 269, 1001  
Jordan VC, 745  
Jørgensen J, 1135  
Jortner BS, 257  
Joyce RP, 1119

**K**

- Kalman SM, 1223  
Kaplan BH, 717, 1005  
Kaplan R, 1359  
Kaplan WD, 1217  
Karakousis CP, 819  
Karon M, 381  
Kaye SB, 1161  
Keating MJ, 279  
Kelly DR, 997  
Kelsen DP, 345, 705  
Kemeny NE, 349, 1149  
Kemp JV, 761  
Kempin SJ, 951  
Kenis Y, 1341  
Kennedy BJ, 331, 487, 997, 1159  
Kensler TW, 967  
Kessler W, 709  
Kies MS, 1119  
King GW, 251  
Klag M, 1227  
Klastersky J, 1341  
Klefström P, 65  
Klein L, 1109  
Klotz J, 507  
Knebel K, 889  
Kochi M, 21  
Koeffler HP, 105  
Kogelnik HD, 263  
Komaki R, 957  
Kovach JS, 993  
Koyama Ya., 861  
Koyama Yo., 861  
Koziol D, 1087  
Krakoff IH, 837, 1319  
Kravit W, 625, 1061  
Kuberka N, 1367

**Kubota TT, 1**

- Kufe DW, 1067, 1307  
Kuhn JA, 1083  
Kun LE, 957  
Kutas GJ, 1123  
Kvols LK, 87, 721, 925, 1057, 1388  
Kwong R, 331

**L**

- Laing L, 797  
Lange PH, 381  
Larsson G, 639  
Laufman LR, 675  
Lawrence BV, 731  
Lazarus H, 231  
Leake RE, 797  
Lee CKK, 175  
Legha SS, 157, 909, 929  
Lehotay DC, 1127  
Leichman LP, 1139  
Leikin S, 381  
Leimert JT, 301, 649, 1389  
Lein JM, 73  
Lele S, 1379  
Lelli G, 1181  
Lenox-Smith I, 263  
Lenzofer R, 41  
Le Pecq J-B, 879  
LeRoy AF, 123  
Lesnick GJ, 361  
Lessner HE, 1359  
Leventhal BG, 435  
Levey BA, 1127  
Levey GS, 1127  
Levi JA, 1011  
Levin DC, 1217  
Levin VA, 237, 1179  
Levine BS, 855, 1031, 1207, 1211  
Levitt SH, 175  
Lewis KP, 1162  
Libert P, 1341  
Libretti A, 845  
Lichtenfeld JL, 1335  
Liepmann MK, 943  
Lippman ML, 1015  
Lipton A, 731  
Litterst CL, 203  
Livingston RB, 1241  
LoBuglio A, 1387  
Lo Gerfo P, 1371  
Lokich JJ, 305, 905  
Longeval E, 1341  
Loo TL, 279, 285  
Loose L, 915  
Lopez RE, 819  
Lovett JM, 1389  
Lowe L, 105  
Luckert PH, 1323  
Lynch G, 1149

**M**

Macbeth FR, 797  
Macdonald JS, 1051  
Magill GB, 1129, 1247  
Magin RL, 203  
Maguire LC, 301  
Mahesh Kumar AP, 11  
Mairesse P, 1341  
Malspeis L, 251  
Mandel E, 1169  
Mandelli F, 939  
Mangioni C, 845  
Manni A, 111, 779  
Markus S, 1009  
Marsoni S, 845  
Marti JR, 285  
Martin DS, 1169  
Martini A, 897  
Martini N, 539  
Martino S, 161  
Mashiter K, 1073  
Matsumoto Y, 21  
McCormack JJ, 837  
McCracken JD, 675, 1387  
McCredie KD, 1295  
McGovren JP, 727  
McGregor D, 1235  
McMahon LJ, 1241  
McShan D, 425  
McSherry JW, 1319  
Meakin JW, 787  
Medina WD, 1162  
M'girian R, 915  
Mehta BM, 1261  
Meier CR, 599  
Memo R, 553  
Merrin CE, 225  
Meshad MW, 1067  
Metter GE, 1109  
Metz EN, 553  
Meyskens FL, Jr, 171  
Michel J, 1341  
Micheo EQ, 73  
Microcha CJ, 1061  
Mihich E, 211  
Miller DR, 381  
Miller HC, 225  
Miller TP, 1001, 1241  
Minna JD, 539  
Mittelman A, 697  
Mizutani T, 21  
Moayeri H, 697  
Mobbs BG, 787  
Mochizuki K, 21  
Moertel CG, 311  
Moisand C, 879  
Montgomery JA, 987  
Moore EC, 285  
Moore R, 819  
Morales M, 679

Moran M, 701  
Moran RE, 81  
Morasca L, 845  
Morgan DB, 581  
Morgan LR, 225  
Moriarty JK, Jr, 1083  
Morrison FS, 985  
Morrow GR, 451  
Moukhtar M, 1005  
Mouridsen HT, 635  
Muggia FM, 1, 539, 669  
Multhauf P, 507  
Murphy SG, 1329  
Murray GB, 355  
Musso A, 73  
Muzard G, 879  
Myers CP, 1275  
Myers RE, 787

**N**

Naeher C, 1367  
Nair KG, 697  
Nakajima E, 575  
Nakamura K, 575  
Nash AG, 1073  
Natale N, 845  
Natale RB, 345, 1301  
Nathanson L, 133  
Negendank W, 813  
Neidhart JA, 251, 553, 675  
Neijt JP, 323  
Nesbit M, 381  
Newell GR, 363  
Newman RA, 837  
Nicaise C, 1341  
Nichols WC, 925, 1057, 1383  
Nishigaki T, 575  
Nissen NI, 1135  
Niz J, 679  
Noriega L, 679  
Norman A, 1275  
Nystrom JS, 1017

**O**

O'Connell MJ, 311, 993, 1355  
Ohnuma T, 25, 617, 1169  
Oken MM, 1355  
Orsini F, 211  
Osoba D, 1123  
Oster MW, 187, 1371  
Ostrow S, 123  
Ottolenghi L, 845

**P**

Pacilli L, 939  
Padavic K, 813

Padgett C, 1153  
Pajak TF, 47  
Panasci LC, 1227  
Pandya MR, 191, 685  
Pannuti F, 1131  
Panther SK, 301  
Paoletti C, 879  
Papa G, 939  
Parapia L, 581  
Parker LM, 1147  
Paroly WS, 47  
Partington JP, 1087, 1097  
Pastore L, 921  
Pathre S, 1061  
Patterson JS, 761, 775, 801  
Paul AR, 1047  
Pavlovsky S, 73  
Pearson OH, 111, 779  
Pearson RW, 327  
Pedersen-Bjergaard J, 1135  
Perloff M, 361  
Pesando JM, 1147  
Piana E, 1131  
Piazza E, 845  
Pihl A, 1375  
Pileggi JE, 73  
Pimentel P, 143  
Pincus C, 629  
Pinedo HM, 319, 323  
Pirovino M, 385  
Piver MS, 549, 1379  
Pizzo PA, 1023  
Pizzolato M, 73  
Pizzuto J, 679  
Plunkett W, 285  
Polk G, 356  
Pollard M, 1323  
Poplack DG, 734  
Port CD, 855, 1031, 1207, 1211  
Powles TJ, 1073  
Pratt CB, 11  
Presant CA, 1109  
Pridun N, 41  
Priest J, 1061  
Pritchard KI, 787, 1123  
Pugh RP, 47, 981, 1387

## Q

Qazi R, 1143  
Quirt IC, 1123

## R

Raabat J, 187, 1371  
Rabin HR, 1087  
Rakowski TA, 1083  
Rambotti P, 685

Ransom JL, 11  
Ravez P, 1341  
Reinhold R, 305  
Reinstein LE, 425  
Reynolds R, 981  
Richman SP, 1329  
Riihimaki DU, 243  
Rivera G, 11  
Rivkin SE, 93  
Rizzardini M, 873  
Roboz J, 1169  
Rodriguez V, 933  
Rodzynek JJ, 1341  
Rogerson B, 1127  
Romero F, 679  
Roozendaal KJ, 323  
Rosen E, 1031, 1207, 1211  
Rosen F, 819  
Rosen G, 1261  
Rosenberg SA, 589  
Rosenthal S, 1115  
Rosowsky A, 1307  
Ross DA, 1347  
Roth JL, 1119  
Rozenweig M, 1  
Rozsa P, 1287  
Rubert M, 1227  
Ruby ED, 732  
Rubin J, 311, 993  
Rubin P, 473  
Rucker N, 975, 1275  
Rudolph A, 1227  
Ruiz E, 1127  
Russ J, 285  
Ryan DH, 869  
Ryden MJ, 981  
Ryssel HJ, 335

## S

Sadée W, 165  
Saito Y, 21  
Salazar OM, 473  
Salimtschik M, 635  
Sallan SE, 963  
Salmon SE, 269  
Salmona M, 873  
Samaan NA, 909  
Samal B, 161  
Samson MK, 1139  
Sarna G, 1077  
Sather H, 381  
Saunders MI, 263  
Schein PS, 1051, 1083  
Scheulen ME, 599  
Schiffer LM, 293  
Schilcher RB, 599  
Schimberg TP, 237  
Schmale AH, 441  
Schmidt CG, 599

Schneider RJ, 53, 183  
Schoenfeld D, 151  
Schreiner GE, 1083  
Schüller J, 41  
Schulz JJ, 147  
Schutt AJ, 311  
Schwade JG, 155  
Scoltock M, 339  
Seager ML, 237  
Sealy R, 263  
Sears HF, 589  
Sedransk N, 419  
Seeber S, 599  
Seeger RC, 975, 1275  
Serrou B, 193  
Sessa C, 845  
Shanmugathasa M, 709  
Sharon M, 1087  
Shaw MT, 247, 985  
Shoemaker D, 275  
Siddiqi N, 1367  
Siddik ZH, 659  
Siegel MM, 975, 1275  
Siegel SE, 975  
Sikic BI, 659  
Silverman M, 305, 1153  
Silverstein MN, 1355  
Simon R, 405, 589  
Simonsen E, 639  
Simpson DP, 1283  
Sinkovics JG, 93  
Skinner DG, 1077  
Sklaroff RB, 1247  
Sladek NE, 1061  
Slater SR, 741  
Slavik M, 1051  
Slayton RE, 353  
Smith C, 243  
Smith CE, 725  
Smith EH, 1217  
Smith F, 1051  
Smith RB, 1077  
Smith TL, 373  
Smythe T, 1051  
Snel S, 635  
Soares N, 734  
Soloway MS, 225  
Somtag RW, 335  
Sordillo PP, 345, 1129  
Speckhart VJ, 147  
Spector GB, 989  
Spiegel RJ, 1023  
Spoor RP, 915  
Spremulli E, 147  
Stanhope CR, 1139  
Stanley KE, 1017  
Staquet MJ, 519  
Stark J, 1147  
Staubus AE, 251  
Steele GD, Jr, 1217  
Steele N, 219

Sternson L, 765  
Stewart DJ, 1253, 1295  
Stolear JC, 1341  
Straus DJ, 1157  
Straus MJ, 81  
Strong JM, 155, 275  
Struyvenberg A, 323  
Stuckey WJ, 869, 985  
Suárez A, 73  
Suer RP, 327  
Suh K, 1367  
Sutherland DJA, 787  
Swenerton KD, 805  
Sylvester RJ, 519

## T

Taetle R, 611  
Takeuchi S, 21  
Takvorian RW, 1217  
Talle K, 1103  
Tanaka M, 575  
Tashima CK, 279  
Tejada F, 701  
Theodorakis M, 1227  
Theologides A, 997  
Thigpen T, 93  
Thiriaux J, 1341  
Thompson EI, 399  
Thomson DB, 787  
Thorud E, 1089  
Tisman G, 829  
Tonnesen GL, 963  
Tormey DC, 191, 1015  
Torri S, 343  
Totsuka S, 575  
Townsend JJ, 237  
Tretton M, 1223  
Tribaldo M, 939  
Triplett DA, 327  
Tropé C, 639  
Trowbridge AA, 985  
Trowbridge RC, 997  
Trujillo JE, 111  
Tschoopp L, 335  
Tullis J, 305  
Turner AR, 1097  
Turner MA, 243  
Tyagi AK, 967

## U

Upton D, 275  
Urtasun RC, 1087, 1097

## V

Vaitkevicius VK, 1139  
Valdivieso M, 285, 1295

Valenstein S, 1359  
Van-Bac N, 879  
Van Echo DA, 339, 1009, 1335  
van Eys J, 989  
van Hoesel QGCM, 319  
van Lindert ACM, 323  
Van Ryzin J, 503  
Van Vleet JF, 315  
Varansi UR, 1283  
Vaughn C, 675  
Vendrik CPJ, 323  
Vial RH, 869  
Vietti TJ, 457  
Villani F, 353  
Vitale L, 381  
Voakes JB, 171  
Vogel CL, 1153  
Vogelzang NJ, 997, 1159  
Vogl SE, 717, 1005, 1143  
Von Hoff DD, 356, 734  
Vosika GJ, 997

## W

Wakeling AE, 741  
Walker K, 1087  
Wallens WT, 1367  
Wampler GL, 147  
Wang Y-M, 989  
Warrell RP, Jr, 1157  
Waxman S, 1169  
Weerts D, 1341  
Wehling M, 123  
Wein A, 343, 813  
Weiner JM, 981  
Weiner MW, 1223  
Weiss DW, 481  
Weiss RB, 539  
Wendt AG, 269  
Westerberg H, 117  
Wheeler RH, 943

Whitacre M, 1335  
White RAS, 360  
Wiernik PH, 123, 339, 1009, 1335, 1392  
Wiesenfeld M, 301  
Wilson CB, 237, 1179  
Wilson HE, 247, 869  
Wiltshaw E, 689  
Wise H, 553  
Wiseman CL, 157  
Wiseman CW, 929  
Wittenberg BK, 133  
Wittes RE, 179, 693, 1141  
Wolfe LC, 963  
Wollner D, 717  
Wolter J, 151  
Woodcock TM, 53, 183, 1149  
Woolley PV, 1051  
Workman P, 360  
Wright DC, 237  
Wu SJG, 829

## Y

Yagoda A, 183, 1301  
Yap B-S, 93, 1253  
Yap H-Y, 157, 279  
Young CW, 53, 179, 219, 693, 705, 951, 1141, 1157, 1247,  
1301  
Young D, 251  
Yuhas JM, 57  
Yunis A, 1359

## Z

Zaharia M, 701  
Zelen M, 525  
Zia PK, 243  
Zigelboim J, 1077  
Zimmerman HJ, 1023

